ERECTILE dysfunction (ED) is being targeted as a potential objective for Exopharm's regenerative therapy exosomes through stimulating the regenerative and healing capacities of the body,
Exopharm Limited has been testing its exosomes, which are natural cellular particles secreted by stem cells, and purified, to test their ability to reverse post-operative tissue damage, and hopefully reversing erectile dysfunction.
"Animal studies show that exosomes have great potential for reversing a variety of conditions that affect the human 'health span,' which is defined as the number of healthy, functional years that a person lives," said Exopharm Chief Executive Officer, Dr Ian Dixon, who added that while Viagra and a variety of drugs used to address ED were effective to treat symptoms, they rarely impact damaged tissue.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Feb 20
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Feb 20
